OncoMatch/Clinical Trials/NCT06781983
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Is NCT06781983 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies IPH4502 for advanced or metastatic solid tumors.
Treatment: IPH4502 — This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Required: NECTIN4 overexpression
Prior therapy
Must have received: systemic therapy — locally advanced or metastatic
Prior systemic treatment for locally advanced or metastatic disease
Lab requirements
Blood counts
adequate hematological function
Kidney function
adequate organ function
Liver function
adequate organ function
Adequate organ function and hematological function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital - Boston · Boston, Massachusetts
- John Theurer Cancer Center · Hackensack, New Jersey
- Mount Sinai Tisch Cancer Center · New York, New York
- NEXT Oncology - Dallas · Dallas, Texas
- NEXT Oncology - Virginia · Fairfax, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify